A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06065540 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2734

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Cagrilintide
DRUG: Semaglutide
DRUG: Placebo cagrilintide
DRUG: Placebo semaglutide

Sponsor

Novo Nordisk A/S